Microbiotica raises £36m in Series C financing

IP Group increases its stake in Microbiotica after a £36m Series C round.

What the company is saying

IP Group plc (LSE: IPO) highlights that its portfolio company Microbiotica Ltd has closed a £36m Series C financing, with IP Group itself investing £4m in the round. The announcement frames this as a step forward for Microbiotica’s pipeline, specifically advancing MB310 into Phase 2 clinical development for ulcerative colitis. The company emphasizes positive results from the COMPOSER-1 Phase 1b study, stating it met both primary and secondary endpoints and showed statistically significant improvements in clinical remission versus placebo, though no detailed data is provided. The release names British Business Bank as the lead investor, with participation from Tencent, Cambridge Innovation Capital, Flerie Invest, and Seventure Partners. Greg Smith, Chief Executive of IP Group, is quoted expressing confidence in Microbiotica’s progress and the strength of the investor syndicate. The tone is optimistic, focusing on the potential of Microbiotica’s proprietary microbiome profiling platform and the value of IP Group’s now 16.4% undiluted holding, valued at £24.1m.

What the data suggests

The announcement confirms that Microbiotica has secured £36m in new capital, a substantial funding round for a clinical-stage biopharma. IP Group’s £4m investment results in an undiluted 16.4% beneficial holding in Microbiotica, valued at £24.1m after the second completion. The financing round is led by British Business Bank, with several established investors participating, which signals external validation of Microbiotica’s prospects. The capital is earmarked for advancing MB310 into Phase 2 clinical development, following a Phase 1b study that reportedly met its endpoints and showed statistically significant clinical remission improvements versus placebo, but no specific trial data, p-values, or timelines are disclosed. Microbiotica is also progressing other pipeline assets, including MB097 in immuno-oncology, but again, no granular clinical or operational metrics are provided. The financial disclosures are clear and specific regarding the investment amounts, ownership percentage, and valuation, but the operational and clinical progress is described in broad terms without supporting quantitative evidence.

Analysis

The announcement is upbeat, highlighting the successful closure of a £36m Series C financing round and positive clinical progress for Microbiotica. The realised facts are the capital raise, IP Group's investment, and the resulting ownership stake and valuation. However, the main forward-looking claim is that the new capital will support advancement of MB310 into Phase 2 clinical development, which is a long-term, high-risk process typical for clinical-stage biopharma. While the COMPOSER-1 Phase 1b study is said to have met endpoints, no numerical results or timelines for Phase 2 are disclosed, and there is no mention of revenue, profit, or near-term commercial milestones. The capital intensity is high, with substantial funds raised but no immediate earnings impact or clear path to monetisation. The tone is somewhat inflated by language such as 'exciting progress' and 'strong foundation,' but the core facts are not misrepresented.

Risk flags

• ●Clinical development risk is high, as progression from Phase 1b to Phase 2 does not guarantee future success or regulatory approval; most clinical-stage biopharma assets fail to reach commercialisation.
• ●The announcement lacks detailed clinical data, such as trial endpoints, p-values, or timelines, making it difficult to independently assess the true efficacy or safety profile of MB310 and other pipeline assets.
• ●Valuation of IP Group’s 16.4% stake at £24.1m is contingent on future clinical and commercial milestones being met; any setbacks in development could materially reduce this value.
• ●The capital-intensive nature of clinical trials means further funding rounds may be required before commercialisation, potentially diluting existing shareholders if results do not meet expectations.

Bottom line

This announcement signals that IP Group has deepened its commitment to Microbiotica, investing £4m in a £36m Series C round and increasing its undiluted holding to 16.4%, now valued at £24.1m. The round is backed by a reputable syndicate, providing external validation, but the operational progress is described in general terms without detailed clinical data or timelines. The main catalyst—advancement of MB310 into Phase 2 trials—remains a long-term, high-risk proposition, with no near-term commercialisation in sight. Investors should recognize that while the funding and syndicate quality are positives, the lack of granular clinical results and the inherent risks of drug development mean that value realisation is uncertain and likely years away. The most important takeaway is that this is a capital-raising and pipeline-advancement milestone, not a near-term revenue or profit event.

Announcement summary

(LSE: IPO) IP Group plc announced that its portfolio company Microbiotica Ltd has closed a £36m Series C financing round. Microbiotica is a clinical-stage biopharma company developing orally-dosed, precision microbiome medicines. The capital raised will support the advancement of Microbiotica's lead programme, MB310, into Phase 2 clinical development for ulcerative colitis. This follows positive results from the COMPOSER-1 Phase 1b study, which met both its primary and secondary endpoints and showed statistically significant improvements in clinical remission compared to placebo. IP Group invested £4m in this financing round, which was led by British Business Bank and included participation from Tencent, Cambridge Innovation Capital, Flerie Invest, and Seventure Partners. After the second completion of the financing, IP Group will hold an undiluted beneficial interest of 16.4% in Microbiotica, valued at £24.1m. Microbiotica is also advancing a pipeline of immuno-oncology programmes, including MB097 in combination with KEYTRUDA® (pembrolizumab) for advanced melanoma, which has met its trial endpoints and is progressing through a Phase 1b extension phase. Microbiotica's proprietary, genomics-driven microbiome profiling platform enables precision identification of bacteria associated with favourable clinical trial outcomes in specific patient populations. The company was spun out of the Wellcome Sanger Institute in 2016 and is based at Chesterford Research Park near Cambridge, UK. Microbiotica is backed by British Business Bank, Cambridge Innovation Capital, Flerie Invest, IP Group plc, Seventure Partners, and Tencent. The company has also received financial support from the US-based Crohn's and Colitis Foundation. Greg Smith, Chief Executive of IP Group, commented that Microbiotica has made exciting progress in translating microbiome science into potential new medicines and that the positive results from MB310 provide a strong foundation for its next stage of development.

Disagree with this article?